Gut bacteria could hold key to better colon cancer detection

NCT ID NCT06741293

Recruiting now Knowledge-focused Sponsor: Gulbenkian Institute for Molecular Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to improve early detection of colorectal cancer by analyzing gut bacteria in stool samples from 30,000 people in Portugal aged 40-74. Researchers will compare the microbiome of healthy individuals with those who have precancerous polyps or cancer, looking for unique bacterial signatures. The goal is to develop a more accurate, non-invasive screening test than current methods like the FIT test.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a more accurate, non-invasive stool test for early colorectal cancer detection, potentially saving lives through earlier diagnosis.
What could go wrong: This is an observational study, not a treatment trial. It may not identify reliable biomarkers, and any new test would require further validation in larger studies before clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER (CRC) COLORECTAL CANCER SCREENING MICROBIOME

Contacts and locations

Locations

Gulbenkian Institute for Molecular Medicine
RECRUITING

Lisbon, Lisbon District, 1649-028, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.